How Low Should We Go?
Upton, J.; Eiwegger, T. (Toronto, Ont.)

Cost-Effectiveness of Immunotherapy in the Treatment of Seasonal Allergic Rhinitis: Identifying Product-Specific Parameters of Relevance for Health Care Decision-Makers and Clinicians
Bachert, C. (Ghent); Noergaard Andreasen, J. (Hørsholm)

The House Dust Mite Major Allergen Der p 23 Displays O-Glycan-Independent IgE Reactivities but No Chitin-Binding Activity
Soh, W.T. (Bangkok); Le Mignon, M. (Antony); Suratannon, N.; Satitsuksanoa, P.; Chatchatee, P.; Wongpiyaboron, J.; Vangveravong, M.; Rerkpattananipat, T.; Sangasapaviliya, A. (Bangkok); Nony, E. (Antony); Piboonpocanun, S. (Nakhon Pathom); Ruxrungham, K.; Jacquet, A. (Bangkok); Mite Allergy Research Cohort (MARC) Study Team

Serum Biomarkers of Allergic Contact Dermatitis: A Pilot Study
Zinkevičienė, A. (Vilnius); Kainov, D. (Helsinki/Siauliai); Lastauskiene, E.; Kvedariciene, V. (Vilnius); Bychkov, D.; Byrne, M. (Helsinki); Girkontaitė, I. (Vilnius)

(Continued on inside front cover)
Mechanisms of Allergy

165 Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma

173 Epigenetic Regulation in Early Childhood: A Miniaturized and Validated Method to Assess Histone Acetylation
Harb, H. (Marburg); Amarasekera, M. (Perth, W.A.); Ashley, S. (Parkville, Vic.); Tulic, M.K. (Perth, W.A./Nice); Pfefferle, P.I.; Potaczek, D.P. (Marburg); Martino, D. (Parkville, Vic.); Kesper, D.A. (Marburg); Prescott, S.L. (Perth, W.A.); Renz, H. (Marburg)

182 Dose-Dependent Immunological Responses after a 6-Month Course of Sublingual House Dust Mite Immunotherapy in Patients with Allergic Rhinitis
Didier, A. (Toulouse); Campo, P. (Malaga); Moreno, F. (Cádiz); Durand-Perdriel, F. (Nantes); Marin, A. (Madrid); Chartier, A. (Courbevoie)

Clinical Allergology

193 Serum IL-33 Is Elevated in Children with Asthma and Is Associated with Disease Severity
Bahrami Mahneh, S.; Movahedi, M.; Aryan, Z.; Bahar, M.A.; Rezaei, A.; Sadr, M.; Rezaei, N. (Tehran); Universal Scientific Education and Research Network (USERN)

205 The Heterogeneity Hidden in Allergic Rhinitis and Its Impact on Co-Existing Asthma in Adults: A Population-Based Survey
Antonicelli, L. (Ancona); Marchetti, P.; Accordini, S. (Verona); Bono, R.; Carosso, A. (Turin); Casali, L. (Perugia); Cazzoletti, L. (Verona); Corsico, A. (Pavia); Ferrari, M. (Verona); Fois, A. (Sassari); Nicolini, G. (Parma); Olivieri, M. (Verona); Pirina, P. (Sassari); Verlato, G. (Verona); Villani, S. (Pavia); de Marco, R. (Verona)

Novel Insights from Clinical Practice

197 Negativity for Specific Autoantibodies in Patients with Type 1 Diabetes That Developed on a Background of Common Variable Immunodeficiency
Milota, T.; Šumník, Z.; Obermannová, B. (Prague); Kralíčková, P. (Hradec Králové); Vondrák, K.; Klocperk, A.; Kayserová, J.; Šedivá, A. (Prague); the ESID Registry Working Party

218 Erratum
Guidelines for Authors

International Archives of Allergy and Immunology appears monthly and provides a forum for publication of work from all aspects of modern allergology and immunology. Papers considered of special interest will be treated as ‘hot topics’ and every attempt will be made to publish these especially fast. The Editor-in-Chief, the Managing Editor and a team of internationally established Associate Editors competently covering all fields of allergology and immunology are responsible for the scientific quality of this international core journal. International Archives publishes original work in the fields of allergy, immunopathology and transplantation, cellular immunology, immunogenetics, immunopharmacology and immunodendrocrinology, mucosal immunology, immunology of infectious diseases and immunology of connective tissue diseases. In addition, reviews, minireviews, commentaries and opinions on controversial subjects are published regularly. A new system of manuscript submission, reviewing and processing guarantees competent and fair reviewing as well as fast and high quality publication.

Submission
Only papers written in English are considered. Detailed Online Submission Instructions with a link to the Submission Website are at http://www.karger.com/iaa/. Before submitting your manuscript, you are encouraged to review the detailed guidelines at www.karger.com/iaa_guidelines for specific directions as how to get a manuscript ready for submission. If you should have any problems with your submission, or should you feel the need to submit the paper in a non-electronic form, please contact the editorial office:

S. Karger AG
Editorial Office 'International Archives of Allergy and Immunology'
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1360
Fax +41 61 306 1434
E-Mail: a.zumbrunn@karger.com

Mailing address for courier deliveries only:
Alässchwilerstr. 10
CH–4055 Basel (Switzerland)

Original papers: Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated.

Short communications: These manuscripts should not contain more than 2 printed pages (i.e. 6,460 characters per page), including an abstract, essential references and not more than 3 tables or figures. Such communications should represent complete, original studies and should be arranged in the same way as full-length manuscripts.

Novel Insights from Clinical Practice (formerly Case Reports): The publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable case. Highlighted boxes containing one or two bullet points on ‘Established facts’ (what is already known) and ‘Novel insights’ (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation. The manuscript should be presented with an abstract (unstructured, max. 200 words), followed by introduction, case report and discussion. Maximum 3 figures.

Review articles, minireviews, opinion articles, controversies and commentaries: Authors who wish to contribute a manuscript to one of these categories should contact the Editor-in-Chief. Minireviews should be focused, brief reports on topics of current interest. Commentaries should offer a more personalized perspective on a topic that will be of interest to the general readership. All contributions to these categories will be subject to Editorial review.

Letters to the Editor concerning work published in the journal may be submitted. They should not exceed 2 manuscript pages including one table or figure.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. A cover letter with the name, address, and telephone and telefax numbers of the corresponding author must accompany each manuscript. This letter must include a statement that affirms that all authors agree with the submission. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of International Archives of Allergy and Immunology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. One of the criteria considered in reviewing manuscripts is the proper treatment of animals. In particular, the use of painful or otherwise noxious stimuli must be carefully and thoroughly justified. Papers that do not meet these criteria will not be accepted for publication.

Conflict of Interest
Authors are required to disclose any sponsorship or funding arrangements, including that from companies, relating to their research. All authors should disclose any possible conflicts of interest in the cover letter to the editor and at the end of the article.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the authors will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement
Manuscripts should be written in English and be as concise as possible. Be sure to display line numbers (1, 2, 3, and so forth) in the left margin of the manuscript (line numbering can be added from the Page Setup or Format menu of word processing programs). The line numbering should be continuous throughout the entire manuscript, from the title page through to the final page (i.e., do not begin numbering from 1 again at the top of each page).

Title page: The first page of each paper should indicate a concise title, the authors’ full names, affiliations and the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as an e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Provide on a separate page an abstract of not more than 250 words. This abstract should consist of four paragraphs, labeled Background, Methods, Results, and Conclusions. They should briefly describe, respectively, the problem being addressed in the study, how the study was performed, the salient results, and what the authors conclude from the results.

The text should be arranged in the following sections: Introduction, Material and Methods, Results, Discussion, Acknowledgement, References.

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labeled with its number and the author’s name. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling (final size), line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger.com/iaa/).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

Abbreviations: Avoid oversize of abbreviations. Introduce an abbreviation only when the same term occurs three or more times.
References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors.Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Full address: The exact postal address complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as your e-mail address.

Reference Management Software: Use of EndNote® is recommended for easy management and formatting of citations and reference lists (format setting: Intertwovig).

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be used in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement: ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations [NIH etc.]).

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
• Follow the terms of the relevant Creative Commons license
• Be linked to the final version on www.karger.com
• Include the following statement: ‘The final, published version of this article is available at http://www.karger.com/doi=[insert DOI number]’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges
There are no page charges for papers of 5 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is 5 printed pages (6,460 characters per page), which is equal to approx. 14 manuscript pages including tables, illustrations and references.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
Hauptvorträge
Freitag, 20. Mai 2016, 14:00 - 16:00 Uhr
Prof. L. Klimek
Differenzierte Therapie der Sinusitis
M. Auge
Nutzen und Grenzen der Allergenkennzeichnung bei Lebensmitteln

Hauptvorträge
Samstag, 21. Mai 2016, 09:00 - 13:30 Uhr
Vorsitz: Prof. K. Hörmann, Mannheim  Prof. T. Hirche, Wiesbaden  Prof. R. Mösges, Köln
Prof. J. Mullol, Barcelona
The new frontier for Upper Airway Inflammatory treatment
Prof. M. Lommatzsch, Rostock
Schweres Asthma: Definition, Diagnostik und Therapie
Prof. C. Schmidt-Weber, München
Was passiert bei der allergischen Entzündung in den Atemwegen?
Prof. J. Buters, München
Wie sollte die allergikerfreundliche Stadt aussehen?
Prof. Th. Hummel, Dresden
Riechen und Allergien
Dr. H. Müsken, Bad Lippspringe
Welche Allergene finden sich eigentlich in deutschen Haushalten?
Mehr als Hausstaubmilben...


WORKSHOPS im Parallelprogramm
Workshop I (unterstützt von MEDA):
14:30 - 17:00 Uhr, Dr. P. Enders & Team, Eichen
Der allergologische Notfall / Anaphylaxie: Wie gehe ich in der Praxis vor?

Workshop II:
14:30 - 17:00 Uhr, Dr. B. Hauswald & Dr. Y. Yarin, Dresden
Akupunkturkurs: Grundlagen und HNO-spezifische Behandlungsmethoden mit praktischen Übungen

Workshop III (unterstützt von Aerocrine):
14:30 - 16:00 Uhr, Prof. L. Klimek, Dr. J. Mathews, Dr. V. Mandelbaum & Team
FeNO-Messungen in der Praxis: Praktische Übungen und Hands-on Workshop

Workshop IV (unterstützt von ALK Abelló):
14:30 - 16:00 Uhr, Dr. P. Herfort, Düsseldorf
Milben-Workshop

Workshop V (unterstützt von Phadia Thermofisher Scientific):
14:30 - 16:00 Uhr, Prof. J. Huss-Marp, Wiesbaden
Allergietests mit dem Multiplextest ImmunoCAP® ISAC

„HYDE-PARK im Klostergarten“
Diskussions-Comer (unterstützt von HAL Allergie):
15:00 - 16:30 Uhr, Prof. O. Pfadl, Wiesbaden, Prof. Chr. Termeer, Stuttgart
SIT 2016 - Was bringen uns Evidenz und Zulassung in Gegenwart und Zukunft?
98. Jahresversammlung
98ème Réunion annuelle

CENTRE MÉDICAL
UNIVERSITAIRE
GENÈVE

Wissenschaftliches Programm / Programme scientifique

Plenarvorträge / Session plénière

Key Lecture 1: Ce que le Dermatologue doit savoir en rhumatologie
(Cem Gabay, Genève)

Key Lecture 2: Grosse Moleküle, kleine Poren – topische Therapien der Zukunft / 
Grandes molécules, petits pores – des thérapies topiques pour l’avenir
(Yogehavar N. Kalia, Genève)

Key Lecture 3: Patienten zuhören: warum und wie? / Ecouter les patients: pourquoi, comment?
(Matthias Augustin, Hamburg)

Key Lecture 4: Innovationen in der Dermatochirurgie / Les innovations de la dermatochirurgie
(Gionata Marazza, Bellinzona)

Key Lecture 5: Prophylaxie von venerischen Krankheiten: Geschichte, Kino, Literatur / 
Prophylaxie des maladies vénériennes: histoire, cinéma, littérature
(Charles Wenger, Genève)

Workshop der Arbeitsgruppen SGDV / Ateliers des groupes de travail SSDV

Klinisch-pathologische Korrelationen / Corrélations anatomo-cliniques

Thematische Fallvorstellungen und Diskussion aus den Kliniken / 
Présentation thématiques et discussion de cas cliniques par les services

Freie Mitteilungen / Communications orales

Symposien und Workshops / Symposia et ateliers

Organisiert von / Organisé par:
AbbVie AG, Allergan AG, Amgen Switzerland AG, Celgene GmbH, Eli Lilly (Suissse) SA, 
Galderma Schweiz AG, Janssen-Cilag AG, La Roche-Posay, LEO Pharma, Louis Widmer SA, 
MEDA Pharma GmbH, Novartis Pharma Schweiz AG

Rahmenprogramm / Programme cadre

Abend für die jungen Dermatologen der SGDV (Donnerstag, 25.8.2016)
Soirée pour les jeunes dermatologues de la SSDV (jeudi, 25.8.2016)
Apéro und Nachtfessen während der Schiffsrandfahrt auf dem Dampfschiff «Simplon» (Freitag, 26.8.2016)
Apéritif et Dîner pendant la croisière sur le bateau à vapeur «Simplon» (Vendredi, 26.8.2016)

ANMELDUNG online ab 15.3.2016
INSCRIPTION online dès le 15.3.2016 :
www.derma.ch

ABSTRACT DEADLINE: 30.4.2016
Autoimmune Diseases of the Liver

For the first time the editors of this volume have brought together text, illustrations and high-definition videos to create an expert video atlas in the field of pediatric airway surgery. The publication which includes the book and free online access to the videos provides a detailed review of the pros and cons and clinical pearls involved in various modes of pediatric airway surgery.

Discussed are all the main open airway surgeries including laryngotracheal reconstruction, cricotracheal resection, tracheal resection and re-anastomosis, and slide tracheoplasty. Further covered is a range of endoscopic procedures such as endoscopic repair of laryngeal clefts and endoscopic treatment of vocal fold immobility. The high-definition videos with audio overlay and the text complement provide an excellent detailed instruction manual for surgeons willing to carry out these operations.

This publication is designed for all levels, from medical student through residency and fellowship as well as the pediatric otolaryngologist or pediatric surgeon preparing for pediatric airway surgery.

Contents

Preface: Ginès, P; Beuers, U; Cortez-Pinto, H; Lohse, A.W; Parés, A.

Introductions

Worldwide Incidence of Autoimmune Liver Disease: Jepsen, P; Grenbæk, L; Vistrup, H.

Genetic Risk and the Development of Autoimmune Liver Disease: Karlsen, T.H; Chung, B.K.

Association of Extrahepatic Manifestations with Autoimmune Hepatitis: Wong, G.W; Heneghan, M.A.

Paediatric Autoimmune Liver Disease: Lammers, W.J; Harms, M.H; Hansen, B.E.

Autoimmune Hepatitis

Diagnostic Criteria for Autoimmune Hepatitis: Scores and More: Lohse, A.W.

Role of Histopathology in Autoimmune Hepatitis: Tiniakos, D.G; Brain, J.G; Bury, Y.A.

Primary Biliary Cholangitis

Geoepidemiology, Genetic and Environmental Risk Factors for PBC: Zhang, H; Carbone, M; Lleo, A; Invernizzi, P.

Aspects of the Pathophysiology of Primary Biliary Cirrhosis: Corrigan, M; Hirschfield, G.M.

Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management: Jopson, L; Jones, D.E.J.

Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis: Poupon, R.

Surgrographic Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis: van Buuren, H.R; Lammers, W.J; Harms, M.H; Hansen, B.E.

Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid: Parés, A.

Primary Sclerosing Cholangitis

Diagnosis, Differential Diagnosis, and Epidemiology of Primary Sclerosing Cholangitis: Ponsioen, C.V.

Malignancies in Primary Sclerosing Cholangitis – A Continuing Threat: Bonato, G; Cristofori, L; Strazzabosco, M; Fabris, L.

Therapy of Primary Sclerosing Cholangitis – Today and Tomorrow: Halibasic, E; Fuchs, C; Hofer, H; Paumgartner, G; Trauner, M.

Pathogenesis and Management of Pruritus in PBC and PSC: van Buuren, H.R; de Vries, N; Bories, C; van Buuren, H.R.

Therapy of Primary Sclerosing Cholangitis: Past, Present, and Future: Wiersinga, WJ; Oude Elferink, R.P; Beuers, U.

Therapy of IgG4-Associated Cholangitis – A Mimic of PSC: Beuers, U; Hubers, L.M; van Buuren, H.R; de Vries, N; de Vries, N; Bories, C; van Buuren, H.R.

Therapy of IgG4-Associated Cholangitis: A Mimic of PSC: Beuers, U; Hubers, L.M; van Buuren, H.R; de Vries, N; Bories, C; van Buuren, H.R.

Therapy of IgG4-Associated Cholangitis: A Mimic of PSC: Beuers, U; Hubers, L.M; van Buuren, H.R; de Vries, N; Bories, C; van Buuren, H.R.

Therapy of IgG4-Associated Cholangitis: A Mimic of PSC: Beuers, U; Hubers, L.M; van Buuren, H.R; de Vries, N; Bories, C; van Buuren, H.R.

Therapy of IgG4-Associated Cholangitis: A Mimic of PSC: Beuers, U; Hubers, L.M; van Buuren, H.R; de Vries, N; Bories, C; van Buuren, H.R.

Primary Sclerosing Cholangitis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid: Parés, A.

Overlap Syndromes: Chazouillères, O.
The journal’s aim is to increase the distribution of scientific knowledge in the new discipline of medical epigenetics. Epigenetics, a rapidly emerging scientific discipline, seeks to define how the genome is regulated to produce distinct normal and diseased phenotypes. Epigenomics, the genome-wide application of epigenetic techniques, is at the core of systems biology extending the power of genomics, proteomics, and other high throughput techniques for the analyses of complex phenotypes.

Medical Epigenetics seeks to catalyze discoveries and genome-wide applications in the areas of gene regulation, chromatin dynamics, and epigenetic inheritance to disease-oriented research. Articles will be focused on disseminating scientific advances and applications of this field to mapping DNA methylation, histone modifications, chromatin accessibility and small RNA transcripts in cells, tissues and organ systems frequently involved in human disease. This journal is also committed to support development, standardization and sharing of protocols, reagents and analytical tools to enable the research community to utilize, integrate and expand upon this new exciting biomedical discipline.

More information at www.karger.com/mee
Medical Statistics has never been easier!

David E. Matthews
Vernon T. Farewell

Using and Understanding Medical Statistics
5th, revised and extended edition

The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the ‘heavy lifting’.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for over-dispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.

Contents

Preface to the Fifth Edition
Prefaces to the Previous Editions

• Basic Concepts
• Tests of Significance
• Fisher’s Test for 2 × 2 Contingency Tables
• Approximate Significance Tests for Contingency Tables
• Some Warnings concerning 2 × 2 Tables
• Kaplan-Meier or ‘Actuarial’ Survival Curves
• The Log-Rank or Mantel-Haenszel Test for Comparing Survival Curves
• An Introduction to the Normal Distribution
• Analyzing Normally Distributed Data
• Linear Regression Models for Medical Data
• Binary Logistic Regression
• Regression Models for Count Data
• Proportional Hazards Regression
• The Analysis of Longitudinal Data
• Analysis of Variance
• Data Analysis
  • The Question of Sample Size
  • The Design of Clinical Trials
  • Further Comments regarding Clinical Trials
  • Meta-Analysis
  • Epidemiological Applications
  • Diagnostic Tests
  • Agreement and Reliability

References
Subject Index

The easiest way to order: www.karger.com/medical_statistics

Matthews, D.E. (Waterloo, Ont.);
Farewell, V.T. (Cambridge)

Using and Understanding Medical Statistics
5th, revised and extended edition

1303 x 1433 mm / 499 x 499 pt

CHF 49.00 / EUR 46.00 / USD 54.00

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland

Dear Librarian
I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Downloaded by: 54.70.40.11 - 10/6/2017 10:07:53 PM